Our mission begins with the word cure. We recognize groundbreaking research will lead us toward the cures we seek. For more than 70 years, LLS support has been instrumental in the development of nearly every breakthrough in blood cancer treatment.

CURRENT FUNDING OPPORTUNITIES:

The Career Development Program (CDP) is now open. Eligibility requests are due October 18, 2024.

🚨NEW PROGRAM ALERT🚨 The new Research Accelerator for Follicular Lymphoma (RAFL) Program is now open. Letters of Intent are due September 9, 2024.

The Academic Clinical Trials Program (ACT) is now open. Letters of Intent are due August 1, 2024.

The Underrepresented Minority Medical Student Research Program (URM) is open! Applications are due December 15, 2024.

Applications are now open for the Equity in Access Research Program. Letters of Intent are due September 12, 2024.

Our Research Grant portfolio contains programs that cover blood cancer research from the earliest phase of discovery science to translational research that goes from “Bench to Bedside” directly benefiting our patients. We also strongly believe that providing support to today's promising early-career scientists is fundamental to making sure that they will continue contributing to blood cancer research as tomorrow's leaders of the field.

We announce special, disease focused RFPs (requests for proposal) on a regular basis to accelerate research areas with high unmet need.

To move the needle further and faster, LLS forms partnerships with other organizations to fund meritorious blood cancer research together: